Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux in Mucinous Gastrointestinal Adenocarcinoma
NCT00162110Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2004
- Primary completion
- Jan 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in mucinous adenocarcinoma of the gastrointestinal tract (MAC), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Started Nov 2004; status: completed.
02
Drugs
KL-140
03
Conditions
mucinous adenocarcinoma of the gastrointestinal tract (MAC)
Beyond the preview
Go deeper on NCT00162110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162110.